SC 13D/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. ___8_____)*

SunLink Health Systems, Inc.

(Name of Issuer)

Common Stock, without par value

(Title of Class of Securities)

86737u102

(CUSIP Number)

Ryan Corton

Harwood Capital LLP

6 Stratton Street

London W1J 8LD England

44 (0)20 7640 3202

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

June 28, 2007

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

^* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 86737u102 13D Page 2 of  Pages

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Harwood Capital LLP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ¨ (b)    X
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions)   AF
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION   England

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER   0
		8.	SHARED VOTING POWER   796,546
		9.	SOLE DISPOSITIVE POWER   0
		10.	SHARED DISPOSITIVE POWER   796,546
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 796,546
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) PN, IA
14.	TYPE OF REPORTING PERSON (see instructions)

CUSIP No. 86737u102 13D Page 3 of  Pages

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Christopher Harwood Bernard Mills
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ¨ (b)    X
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions)   AF
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION   England

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER   0
		8.	SHARED VOTING POWER   796,546
		9.	SOLE DISPOSITIVE POWER   0
		10.	SHARED DISPOSITIVE POWER   796,546
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 796,546
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    ¨
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) IN
14.	TYPE OF REPORTING PERSON (see instructions)

CUSIP No. 86737u102 13D Page 4 of  Pages

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) North Atlantic Smaller Companies Investment Trust Plc
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a)    ¨ (b)    X
3.	SEC USE ONLY
4.	SOURCE OF FUNDS (see instructions)  WC
5.	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨
6.	CITIZENSHIP OR PLACE OF ORGANIZATION  England

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7.	SOLE VOTING POWER   0
		8.	SHARED VOTING POWER  745,402
		9.	SOLE DISPOSITIVE POWER   0
		10.	SHARED DISPOSITIVE POWER   745,402
11.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 796,546
12.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    ¨ 10.7%
13.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) OO, IA
14.	TYPE OF REPORTING PERSON (see instructions)

CUSIP No. 86737u102 13D Page 5 of  Pages

Item 1.  Security and Issuer.  

The class of equity securities to which this Amendment relates is  the common wstock, without par value (the “Common Stock”), of SunLink Health Systems, Inc., an Ohio corporation (the “Company”). The principal executive offices of the Company are located at 900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339.

Item 2.  Identity and Background.

2(a-c, f)

I.Filing Parties:  

This Amendment is filed on behalf of the following persons, who are collectively referred to as the “Filing Parties” :

1.Harwood Capital LLP, formerly known as North Atlantic Value LLP (“Harwood Capital”) is a limited liability partnership organized under the laws of England with its principal office and business at 6 Stratton Street, London W1J 8LD England. Harwood Capital is a firm authorized by the United Kingdom’s Financial Conduct Authority and its principally engaged in the business of investment management of active value and private equity investments, as well as to its private clients.  

2.Christopher Harwood Bernard Mills is a British citizen whose business address is 6 Stratton Street, London W1J 8LD England.  His principal employment includes service as director and chief executive of North Atlantic Smaller Companies Investment Trust plc (“NASCIT”) and as chief investment officer and member of Harwood Capital. Mr. Mills has not been convicted in a criminal proceeding during the last five years and has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Mr. Mills is a British citizen. 

3.North Atlantic Smaller Companies Investment Trust Plc (“NASCIT”) is a corporation organized under the laws of England with its principal office and business at 6 Stratton Street, London W1J 8LD England.  NASCIT is a publicly-held investment trust company. Christopher Harwood Bernard Mills is director and chief executive of NASCIT and Harwood Capital acts as manager.  

Item 3.  Source or Amount of Funds or Other Consideration.

NASCIT acquired the following number of common shares at the prices and on the dates indicated.  Each acquisition was made for investment purposes out of its available working capital funds. 

Date of Acquisition	# of Common Shares Acquired	Price Per a Share (USD)
February 16, 2007	392,056	7.0000
June 12, 2007	5,044	6.5436
June 13, 2007	2,900	6.7086
June 11, 2008	269,798	0.0000
June 19, 2008	6,202	4.8000
February 12, 2009	300,000	0.8000
July 19, 2011	424,000	1.9100

Item 4.  Purpose of Transaction.

On June 28, 2007, the Sunlink Health Systems, Inc. (the “Company”) and North Atlantic Value LLP now known as Harwood Capital LLP (“Harwood Capital”) agreed to elect Christopher H.B. Mills as a director of the Company on certain understandings, including that neither Mr. Mills nor any of his affiliates would propose to publicly effect (i) an acquisition of any securities of the Company that would effect a change in control of the Company, (ii) any tender offer, merger or other business combination involving the Company, (iii) liquidation, dissolution or other extraordinary transaction with respect to the Company (iv) solicit proxies of voting securities of the Company. In addition, Mr. Mills agreed to resign his position as director if the holdings of his group falls below 5% of the fully diluted common shares of the capital stock of the Company.  Further understandings are described in the letter, which is attached as Exhibit 99.2 to this Amendment on Schedule 13D (the “Letter Agreement”).  

NASCIT acquired the following number of common shares at the prices and on the dates indicated.  Each acquisition was made for investment purposes out of its available working capital funds. 

Date of Acquisition	# of Common Shares Acquired	Price Per a Share (USD)
February 16, 2007	392,056	7.0000
June 12, 2007	5,044	6.5436
June 13, 2007	2,900	6.7086
June 11, 2008	269,798	0.0000
June 19, 2008	6,202	4.8000
February 12, 2009	300,000	0.8000
July 19, 2011	424,000	1.9100

On December 28, 2017, NASCIT disposed of 654,596 shares of common stock of the Company and Harwood Capital LLP disposed of 44, 915 shares of common stock of the Company, pursuant to the Company’s Offer to Purchase dated November 21, 2017, as amended December 7, 2017. The Issuer’s stated purpose in making its Offer to Purchase was to return capital to its shareholders. 

No Filing Party currently has no plans or proposals which relate to or would result in:

(a) the acquisition of additional securities of the Issuer, or the disposition of securities of the Issuer; provided, however, Mr. Mills presently has options which, if exercised, would entitle him to acquire 5,000 Common Shares of the Company;

(b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries;

(c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

(d) any change in the present Board of Directors or management of the Issuer;

(e) any material change in the present capitalization or dividend policy of the Company;

(f) any other material change in the Issuer’s business or corporate structure;

(g) changes in the Company’s charter or Code of Regulations or other actions which may impede the acquisition of control of the Company;

(h) any class of securities of the Issuer being delisted from a national securities exchange; or

(i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the Securities Exchange Act.

Item 5.  Interest in Securities of the Issuer.

The aggregate number and percentage of the outstanding Common Stock of the Company beneficially owned (i) by each of the Filing Parties, and (ii) to the knowledge of the Filing Parties, by each other person who may be deemed to be a member of the group, is as follows: 

Filing Party	Aggregate Number of Shares	Number of Shares: Sole Power to Vote	Number of Shares: Shared Power to Vote	Number of Shares: Sole Power to Dispose	Number of Shares: Shared Power to Dispose	Approximate Percentage*
Harwood Capital+	796,546	0	796,546	0	796,546	10.7%
Christopher H.B. Mills+	796,546	0	796,546	0	796,546	10.7%
NASCIT	745,402	0	745,402	0	745,402	10.1%

*Based on 7,416,814 shares of Common Stock, without par value, outstanding as of May 11 2018, which is based on information reported in the Company’s 10-Q for the quarterly period ended March 31, 2018.

+ Consists of 745,402 shares of Common Stock, without par value, held by NASCIT and 51,144 shares of Common Stock, without par value, held by certain of private clients of Harwood Capital.  

In the 60 days prior to the date of this Amendment, the Filing Parties effected no transaction in the Common Stock.

Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Harwood Capital has certain arrangements with the Company regarding its actions as shareholder described in the Letter Agreement. Harwood Capital is the investment manager and/or investment adviser to NASCIT and its private clients and as such it has the authority to vote or dispose of the Common Stock. Christopher Harwood Bernard Mills is the chief executive of NASCIT.  Christopher Harwood Bernard Mills is also an indirect owner and chief investment officer of Harwood Capital.

Item 7.  Material to Be Filed as Exhibits.

99.1Joint Filing Agreement dated as of September 14, 2018 among the Filing Parties. 

99.2Agreement of Understanding between SunLink Health Systems, Inc. and Christopher H.B. Mills regarding service as a director.  

Schedule A

Information Concerning Directors and Executive Officers of the Filing Parties

The following table sets forth certain information concerning each of the members and partners of Harwood as of the date hereof:

Members:

Name: Jeremy James Brade 

(Member) 

Citizenship: British 

Business Address:                6 Stratton Street 

London, W1J 8LD 

England 

Principal Occupation: Member, Harwood Capital 

Name: James Douglas Agnew 

(Member) 

Citizenship: British 

Business Address:6 Stratton Street 

London, W1J 8LD 

England 

Principal Occupation: Member, Harwood Capital  

Name: Keith Andrew Jelley 

(Member) 

Citizenship: British 

Business Address:6 Stratton Street 

London, W1J 8LD 

England 

Principal Occupation: Member, Harwood 

Name: Timothy James Sturm 

(Member) 

Citizenship: British 

Business Address:6 Stratton Street 

London, W1J 8LD 

England 

Principal Occupation: Member, Harwood Capital 

Name:Christopher Harwood Bernard Mills 

(Chief Investment Officer and Indirect Owner through Harwood Capital Management Limited) 

Citizenship:British 

Business Address:6 Stratton Street 

London, W1J 8LD 

England 

Principal Occupation:Chief Executive, NASCIT 

Chief Investment Officer, Harwood 

EX-99.1

Exhibit 99.1
			JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Scheduled 13D
dated September 28, 2018 with respect to the shares of Common Stock,
without par value, of Sunlink Health Systems, Inc. and any further
amendments thereto executed by each or any of us shall be filed on behalf
of each of us pursuant to and in accordance with the provisions of Rule
13d-1(k) under the Securities Exchange Act of 1934, as amended.

This Agreement may be executed in separate counterparts, each of which
shall be deemed an original, but all of which shall constitute one and
the same instrument.

DATED: September 28, 2018








HARWOOD CAPITAL LLP

/s/ Christopher H.B. Mills
Name: Christopher H.B. Mills
Title:


CHRISTOPHER H. B. MILLS

/s/ Christopher H.B. Mills



NORTH ATLANTIC SMALL COMPANIES INVESTMENT TRUST PLC
/s/ Christopher H.B. Mills
Name: Christopher H.B. Mills
Title:  Chief Executive Officer

{}

EX-99.2

Exhibit 99.2



00 Circle 75 Parkway, Suite 1120
Atlanta, Georgia 30399
770-933-7000
770-933-7010 Fax
www. sunlinkhealth.com


June 28, 2007

Mr. Christopher H.B. Mills
Partner
North Atlantic Value LLP
14 Ryder Street
England


Dear Christopher:

I am pleased to advise you that the Board of Directors of SunLink Health
Systems, Inc. is agreeable to electing you to serve as an eighth director
commencing July 9, 2007 upon the following understandings:

(1)
you will be responsible for your travel expenses associated with attending
meetings of the Board;


(2)
you will otherwise be compensated for Board service in the same manner
as other directors;


(3)
should you be unable to attend meetings in person, you may arrange to attend
by telephone conference call;


(4)
you will be subject to and agree to abide by the same policies, including the
corporate code of conduct and limitations on trading, applicable to SunLink
directors;


(5)
you agree that during your period of service as a director and for a period of
90 days thereafter, unless specifically requested to do so by a majority of the
Board of Directors, neither you nor any of your affiliates (as such term is
defined under the Securities Exchange Act of 1934, as amended
(the "1934 Act")) will in any manner, directly or indirectly, (a) propose
publicly to effect, or cause, participate with, or in any way assist, any other
person to propose publicly to effect, (i) any acquisition of the securities
or assets of Sunlink or any of its subsidiaries as would result in a change
in control of Sunlink; (ii) any tender or exchange offer, merger or other
business combination involving SunLink or any of its subsidiaries; (iii)
any liquidation, dissolution or other extraordinary transaction with


Mr. Christopher H.B. Mills
June 28, 2007
Page 2



respect to SunLink or any of its subsidiaries; or (iv) any "solicitation
of "proxies" (as such terms are used in the proxy rules of the
Securities and Exchange Commission) or consents to vote any voting
securities of SunLink; (b) alone or in concert with others, seek to control
or, except in the ordinary course of business in your status as a director
and/or shareholder of SunLink, influence the management, Board
of Directors or policies of SunLink; or (c) take any action which
would reasonably be expected to force SunLink to make a public
announcement regarding any of the types of matters set forth in
(a) above; provided, however, the provisions of subclauses
(i) and (ii) of clause (a), and the provisions of clauses (b) and(c)
(insofar as applicable to such subclauses (i) and (ii) of clause (a)),
of this sentence shall immediately terminate upon the public
announcement of any proposed transaction of the type referred to in
such subclauses (i) or (ii), proposed by SunLink or any third party not
affiliated with you. You also agree during such period not to request
SunLink (or its directors, officers, employees or agents), directly or
indirectly, to amend or waive any provision of this paragraph
(including this sentence).

(6)
You agree to resign your position as a director if the holdings of
your "group" (as defined in the 1934 Act) at any time fall
below 5% of the fully diluted common shares of the capital stock of Sunlink.



Please indicate your agreement with the foregoing by signing and returning
A copy of this letter to me at your earliest convenience.



Very truly yours,


SUNLINK HEALTH SYSTEMS, INC.


By:

/s/ Robert M. Thornton, Jr.


Robert M. Thornton, Jr.
Chief Executive Officer






/s/ Christopher H.B. Mills
Christopher H.B. Mills

{}